Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial Dr Pallavi Mandal, MRCP, James D Chalmers, MRCP, Catriona Graham, MSc, Catherine Harley, MRCP, Manjit K Sidhu, MRCP, Catherine Doherty, PhD, Prof John W Govan, DSc, Prof Tariq Sethi, PhD, Donald J Davidson, PhD, Prof Adriano G Rossi, DSc, Adam T Hill, MD The Lancet Respiratory Medicine Volume 2, Issue 6, Pages 455-463 (June 2014) DOI: 10.1016/S2213-2600(14)70050-5 Copyright © 2014 Mandal et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions
Figure 1 Neutrophil apoptosis after treatment with atorvastatin Neutrophils (per 400 cells counted) are visualised by microscopy in a sample of sputum from a patient after 6 months of treatment with atorvastatin. Apoptotic neutrophils are indicated by arrows. Magnification ×1000. The Lancet Respiratory Medicine 2014 2, 455-463DOI: (10.1016/S2213-2600(14)70050-5) Copyright © 2014 Mandal et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions
Figure 2 Trial profile *Six patients discontinued for the following reasons: alanine aminotransferase level greater than five times the normal value (n=1); diarrhoea (n=1); headache and diarrhoea (n=2); headache (n=1); other reasons (n=1). †One patient discontinued for other reasons. The Lancet Respiratory Medicine 2014 2, 455-463DOI: (10.1016/S2213-2600(14)70050-5) Copyright © 2014 Mandal et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions
Figure 3 Reduction of cough, measured by Leicester Cough Questionnaire LCQ=Leicester Cough Questionnaire. (A) Atorvastatin group. (B) Placebo group. The Lancet Respiratory Medicine 2014 2, 455-463DOI: (10.1016/S2213-2600(14)70050-5) Copyright © 2014 Mandal et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions